Penn Medicine: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania. —> Read More

Investigational personalized cellular therapy tolerated well by patients

Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Perelman School of Medicine at the University of Pennsylvania. The data adds to a growing body of research showing the promise of CAR T cell technology. The interim results will be presented at the American Association for Cancer Research Annual Meeting 2015, April 18-22. —> Read More

Mars Test Rover Joins Runners at Finish Line

Pasadena CA (JPL) Apr 19, 2015

A test rover used during preparations for rover missions on Mars stood in for the NASA Mars rover Opportunity by breaking through the finish-line tape after runners completed a relay marathon at JPL to celebrate Opportunity’s Martian marathon. Eight teams of Earthlings took part, with such appropriate names as “Endeavor Crater” and “Eagle Crater”, in keeping with milestones and locations in the —> Read More

1 2 3 2,545